• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Ian E. Krop, MD, PhD


  • Krop IE.New Research on the Treatment of Small HER2-Positive Breast Cancers.Clin Adv Hematol Oncol. 2014 Feb;12(2):124-7.
  • Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H, .Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.Lancet Oncol. 2014 Jun;15(7):689-99.
  • Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE.A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.Cancer Med. 2014 Apr;3(2):293-9.
  • Krop I, Winer EP.Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.Clin Cancer Res. 2014 Jan 1;20(1):15-20.
  • Krop IE, Burstein HJ.Trastuzumab: qui bono?.Journal of the National Cancer Institute. 2013 Dec 4;105(23):1772-5.
  • Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU.Prospective clinical experience with research biopsies in breast cancer patients.Breast Cancer Res Treat. 2013 Nov;142(1):203-9.
  • Metzger-Filho O, Winer EP, Krop I.Pertuzumab: optimizing HER2 blockade.Clin Cancer Res. 2013 Oct 15;19(20):5552-6.
  • Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M.Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.Breast Cancer Res Treat. 2013 Sep;141(2):255-9.
  • Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU.Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Clin Breast Cancer. 2013 Aug;13(4):254-63.
  • Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.PLoS ONE. 2013;8(6):e67306.
  • Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE.Prevalence of germline TP53 mutations in HER2+ breast cancer patients.Breast Cancer Res Treat. 2013 Apr 12.
  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, .Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med. 2012 Nov 8;367(19):1783-91.
  • Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.Cancer Chemother Pharmacol. 2012 Oct;70(4):591-601.
  • Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH.Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.Clin Cancer Res. 2011 Mar 17.
  • Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.J Clin Oncol. 2011 Feb 1;29(4):398-405.
  • Mayer EL, Krop IE.Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.Clin Cancer Res. 2010 Jul 15;16(14):3526-32.
  • Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.J Clin Oncol. 2010 Jun 1;28(16):2698-704.
  • Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM.Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.J Clin Oncol. 2010 May 20;28(15):2635-40.
  • Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE.Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.Br J Cancer. 2010 May 11;102(10):1495-502.
  • Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME.Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists.Cancer Res. 2010 Mar 15;70(6):2256-63.
  • Tolaney SM,Krop IE.Mechanisms of trastuzumab resistance in breast cancer.Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. Review.
  • Krop IE, Winer EP.Ten years of HER2-directed therapy: still questions after all these years.Breast Cancer Res Treat. 2009 Jan;113(2):207-9.
  • Kleer CG,Bloushtain-Qimron N,Chen YH,Carrasco D,Hu M,Yao J,Kraeft SK,Collins LC,Sabel MS,Argani P,Gelman R,Schnitt SJ,Krop IE,Polyak K.Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.Clin Cancer Res. 2008 Sep 1;14(17):5357-67.
  • Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.J Clin Oncol. 2008 Feb 20;26(6):897-906.
  • Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M.Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?.J Surg Oncol. 2007 Nov 1;96(6):474-80.
  • Krop IE.Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?.Cancer Biol Ther. 2006 Aug;5(8):1039-41.
  • Krop I, Mrz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, Gelman R, Sabel MS, Schnitt S, Ramaswamy S, Kleer CG, Enerbck C, Polyak K.A putative role for psoriasin in breast tumor progression.Cancer Res. 2005 Dec 15;65(24):11326-34.
  • Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K.Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types.Mol Cancer Res. 2004 Sep;2(9):489-94.
  • Krop I, Maguire P, Lahti-Domenici J, Lodeiro G, Richardson A, Johannsdottir HK, Nevanlinna H, Borg A, Gelman R, Barkardottir RB, Lindblom A, Polyak K.Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.Cancer Res. 2003 May 1;63(9):2024-7.
  • Seth P, Krop I, Porter D, Polyak K.Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression).Oncogene. 2002 Jan 24;21(5):836-43.
  • Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K.HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801.
  • Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K.A SAGE (serial analysis of gene expression) view of breast tumor progression.Cancer Res. 2001 Aug 1;61(15):5697-702.
  • Krop IE, Wieczorek TJ, Mayer RJ.Diagnostic dilemmas in oncology. Case 3. Metastatic ovarian cancer simulating colon cancer.J Clin Oncol. 2000 Sep;18(17):3189-92.
  • Krop I, Shaffer AL, Fearon DT, Schlissel MS.The signaling activity of murine CD19 is regulated during cell development.J Immunol. 1996 Jul 1;157(1):48-56.
  • Rolink A, ten Boekel E, Melchers F, Fearon DT, Krop I, Andersson J.A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors.J Exp Med. 1996 Jan 1;183(1):187-94.
  • Krop I, de Fougerolles AR, Hardy RR, Allison M, Schlissel MS, Fearon DT.Self-renewal of B-1 lymphocytes is dependent on CD19.Eur J Immunol. 1996 Jan;26(1):238-42.
  • Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, Krop I, Schlissel MS, Feeney AJ, van Roon M.E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements.Cell. 1994 Dec 2;79(5):885-92.
  • Mehta J, Mehta P, Krop I, Lawson D.The primary wave of epinephrine-induced platelet aggregation represents alpha 2-adrenoceptor status.Thromb Res Suppl. 1988 Mar 15;49(6):531-7.
  • Mehta P, Mehta J, Lawson D, Krop I, Letts LG.Leukotrienes potentiate the effects of epinephrine and thrombin on human platelet aggregation.Thromb Res Suppl. 1986 Mar 1;41(5):731-8.